TY - JOUR T1 - Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive-interstitial lung disease. JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2022.2265 VL - 60 IS - suppl 66 SP - 2265 AU - P Bay AU - M Pineton De Chambrun AU - A Roux AU - V Bunel AU - A Combes AU - D Israël Biet AU - B Zuber AU - H Nunes AU - Y Allenbach AU - Y Uzunhan Y1 - 2022/09/04 UR - http://erj.ersjournals.com/content/60/suppl_66/2265.abstract N2 - Background: Anti-MDA5 dermatomyositis (DM) is a rare subtype of idiopathic inflammatory myopathy, associated with high incidence of rapidly-progressive interstitial lung disease (RP-ILD) with high mortality rate. The use of extracorporeal life support (ECLS) in these patients is questionable, as reported in several studies that emphasize the futility of a bridge-to-recovery strategy. Emergency lung transplantation of previously unlisted patients on ECLS is under debate.Aims and objectives: To describe the outcome of anti-MDA5 RP-ILD patients requiring ECLS.Methods: This French multicenter retrospective study conducted from 2013 to 2021 included all patients with anti-MDA5 RP-ILD requiring ECLS.Results: 15 patients requiring ECLS were included (VV-ECMO n=13, VA-ECMO n=1, ECCO2R n=1). The female-to-male ratio was 4 and the age at ICU admission was 50 [32-67] years. The diagnosis of MDA5 DM was known at ECLS initiation for 8 patients. Five patients underwent lung transplantation after 8 [4-20] days on ECMO, none previously listed for a lung transplant. After a median follow-up of 25 [3-93] months, all transplanted patients were alive and no relapse of DM or ILD was noted. All other patients, not listed for lung transplantation, died after a median of 30 [4-52] days on ECMO.Conclusions: The results provide crucial information for the management of anti-MDA5 RP-ILD. The bridge-to-recovery strategy in anti-MDA5 RP-ILD patients requiring ECLS despite specific prior treatment leads to undesirable results. In contrast, a bridge-to-emergency lung transplantation is not only feasible but also associated with a favorable outcome and appears therefore as the sole hope of survival.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 2265.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -